发布求助
文献互助 智能选刊 最新文献

European Oncology and Haematology最新文献

筛选
英文 中文
Luspatercept for Beta-thalassemia – A New Horizon? 治疗β-地中海贫血的 Luspatercept--新地平线？
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.16
M. A. U. Din, F. Anwer
{"title":"Luspatercept for Beta-thalassemia – A New Horizon?","authors":"M. A. U. Din, F. Anwer","doi":"10.17925/eoh.2020.16.1.16","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.16","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"2 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76232507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thromboprophylaxis – A Neglected Front in Hospitalised Patients with COVID-19 in Pakistan 血栓预防——巴基斯坦COVID-19住院患者中一个被忽视的前沿
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.14
M. A. U. Din, A. Vardag, F. Anwer
{"title":"Thromboprophylaxis – A Neglected Front in Hospitalised Patients with COVID-19 in Pakistan","authors":"M. A. U. Din, A. Vardag, F. Anwer","doi":"10.17925/eoh.2020.16.1.14","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.14","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Regorafenib – Five Years in Review Regorafenib - 5年回顾
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.24
R. Leite, Isabela Demarchi, T. R. Bonatti
{"title":"Regorafenib – Five Years in Review","authors":"R. Leite, Isabela Demarchi, T. R. Bonatti","doi":"10.17925/eoh.2020.16.1.24","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.24","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy in Advanced Prostate Cancer 晚期前列腺癌的免疫疗法
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.44
M. Randhawa, Robert J. Jones
{"title":"Immunotherapy in Advanced Prostate Cancer","authors":"M. Randhawa, Robert J. Jones","doi":"10.17925/eoh.2020.16.1.44","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.44","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"415 1","pages":"44"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78096965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases ALK抑制剂在中枢神经系统转移的ALK阳性NSCLC中的应用
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.18
M. Aldea, B. Besse, L. Hendriks
{"title":"ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases","authors":"M. Aldea, B. Besse, L. Hendriks","doi":"10.17925/eoh.2020.16.1.18","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.18","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 面对转移性非小细胞肺癌的一线-免疫治疗和化疗
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.39
A. D. Toma, G. Russo, D. Signorelli, R. Ferrara, A. Prelaj, G. Galli, G. Viscardi, Benedetta Trevian, M. Ganzinelli, N. Zilembo, F. Braud, M. Garassino, C. Proto
{"title":"Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy","authors":"A. D. Toma, G. Russo, D. Signorelli, R. Ferrara, A. Prelaj, G. Galli, G. Viscardi, Benedetta Trevian, M. Ganzinelli, N. Zilembo, F. Braud, M. Garassino, C. Proto","doi":"10.17925/eoh.2020.16.1.39","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.39","url":null,"abstract":"Journal Publication Date: 15 September 2020 Over the last few years, the treatment of metastatic non-small-cell lung cancer (NSCLC) has completely changed due to the advent of immunotherapy, which dramatically improved prognosis in patients without any driver alterations. First, three distinct immune checkpoint inhibitors (ICIs), nivolumab, pembrolizumab and atezolizumab, became the standard secondor later-line treatments in both squamous and non-squamous NSCLC; later pembrolizumab replaced first-line chemotherapy in advanced NSCLC characterised by programmed death ligand 1 expression of at least 50%. Based on the significant efficacy and safety results using single-agent immunotherapy, ICIs in combination with other ICIs or chemotherapy, have been largely evaluated. In particular, since 2018, several studies combining ICIs and platinum-based chemotherapy as first-line treatment showed impressive results quickly resulting in a promising new standard of care for the near future.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"49 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88162837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development ofHER2-targeted Therapies for Gastrointestinal Cancer her2靶向治疗胃肠道肿瘤的研究进展
European Oncology and Haematology Pub Date : 2020-01-01 DOI: 10.17925/eoh.2020.16.1.29
K. Sawada, Y. Nakamura, K. Shitara
{"title":"Development ofHER2-targeted Therapies for Gastrointestinal Cancer","authors":"K. Sawada, Y. Nakamura, K. Shitara","doi":"10.17925/eoh.2020.16.1.29","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.29","url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"257 1","pages":"29"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91325054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors 复发性卵巢癌的维持治疗——支持PARP抑制剂有效性和安全性的证据
European Oncology and Haematology Pub Date : 2019-09-23 DOI: 10.17925/eoh.2019.15.1.29
R. Coleman, J. Ledermann
{"title":"Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors","authors":"R. Coleman, J. Ledermann","doi":"10.17925/eoh.2019.15.1.29","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.29","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49297216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
DEEP2 Trial – Key Findings in Paediatric Patients with Transfusion-dependent Thalassaemia DEEP2试验-输血依赖型地中海贫血患儿的关键发现
European Oncology and Haematology Pub Date : 2019-01-01 DOI: 10.17925/eoh.2019.15.2.89
A. Kattamis
{"title":"DEEP2 Trial – Key Findings in Paediatric Patients with Transfusion-dependent Thalassaemia","authors":"A. Kattamis","doi":"10.17925/eoh.2019.15.2.89","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.89","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Diagnostics in the Screening, Detection and Diagnosis of Cancer 分子诊断学在癌症筛查、检测和诊断中的应用
European Oncology and Haematology Pub Date : 2019-01-01 DOI: 10.17925/eoh.2019.15.2.84
Sir John Burn
{"title":"Molecular Diagnostics in the Screening, Detection and Diagnosis of Cancer","authors":"Sir John Burn","doi":"10.17925/eoh.2019.15.2.84","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.84","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信